Xaira Exec Divulges R&D Focus, How $1B Fundraise Fuels AI-Driven Hunt for ‘What the Industry Is Hungriest For’

Xaira Therapeutics is beginning to reveal how its $1B raise is powering an AI-first R&D strategy focused on inflammatory and immunological diseases. By building machine learning models like X-Cell from large-scale cellular perturbation data, the company aims to uncover causal biology and develop antibody therapies against high-value targets that have long eluded traditional drug discovery.